Drugs / RSV LID ΔM2-2 1030s
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02952339 | Aug 2016 → Jul 2017 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02794870 | Jul 2016 → Jul 2017 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV LID ΔM2-2 1030s | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02952339 ↗ |
| Modality | Vaccine | “a recombinant live-attenuated respiratory syncytial virus (RSV) vaccine” NCT02794870 ↗ |
| Route | Intranasal | “administered as nose drops” NCT02794870 ↗ |